Clinical trials · Texas
Solid Tumors (Phase 1) clinical trials in Texas
We’re tracking 157 recruiting solid tumors (phase 1) studies with a site in Texas — including Early Phase 1, Phase 1, Phase 1/Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT07505771RecruitingEarly Phase 1
A study of 177Lu-IM-3050 for advanced solid tumors
This trial tests a new treatment called 177Lu-IM-3050 for people with advanced solid tumors that have not responded to or stopped working with standard treatments. The treatment targets a protein called FAP found on some cancer cells and may help shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Houston, TexasAges 18 years+ - NCT05797168RecruitingPhase 1/Phase 2
Early study drug for advanced solid tumors, alone or with another drug
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
Houston, TexasAges 18–130 - NCT06620302RecruitingPhase 1/Phase 2
Adding DT2216 to chemo for relapsed solid tumors and FLC
This trial is testing whether adding a new drug, DT2216, to standard chemotherapy can help treat solid tumors (not starting in the brain) or fibrolamellar carcinoma (FLC) that have come back or not responded to treatment. It's for children, teens, and young adults (ages 1 to 39).
Houston, TexasAges 1–39 - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT07382544RecruitingPhase 1
Study of BMS-986504 with olaparib for MTAP-loss cancers
This trial tests a combination of two drugs (BMS-986504 and olaparib) for people with advanced solid tumors that have a specific genetic change called MTAP loss. It aims to see if this combination can help when standard treatments have stopped working or aren't available.
Houston, TexasAges 18 years+ - NCT07160335RecruitingPhase 1
Testing a potential biosimilar for multiple resected solid tumors
This trial tests whether a new drug, HLX17, works as well as the approved drug Keytruda® in people whose solid tumors (like lung cancer, melanoma, or kidney cancer) have been fully removed by surgery. The goal is to see if the new drug can help prevent the cancer from coming back.
Houston, TexasAges 18–85 - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Dallas, TexasAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Austin, TexasAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Houston, TexasAges 18 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
Fort Worth, TexasAges 18 years+ - NCT05410145RecruitingPhase 1/Phase 2
Study drug for advanced KRAS G12C solid tumors
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Houston, TexasAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Dallas, TexasAges 18 years+ - NCT05307705RecruitingPhase 1
Testing LOXO-783 for PIK3CA-mutated cancers
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Dallas, TexasAges 18 years+ - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
Houston, TexasAges 18 years+ - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
San Antonio, TexasAges 18 years+ - NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Webster, TexasAges 18 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
Irving, TexasAges 18 years+ - NCT06240728RecruitingPhase 1
Testing NPX887 for advanced solid tumors with B7-H7 protein
This trial tests a new drug called NPX887 that targets a protein (B7-H7) on certain cancer cells to help your immune system fight them. It is for people with advanced solid tumors that have not responded to other treatments.
San Antonio, TexasAges 18 years+ - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT06399757RecruitingPhase 1/Phase 2
A study of APL-5125 for advanced solid tumors
This trial tests a new drug called APL-5125 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. If you have certain types of advanced cancer, this study may offer a new option.
Dallas, TexasAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Irving, TexasAges 18 years+ - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Austin, TexasAges 18 years+ - NCT07213791RecruitingPhase 1
Study of a new drug for FAP-positive cancers
This trial tests a new drug (LY4337713) for cancers that have a specific protein called FAP on their surface. It may be an option for people whose cancer has continued to grow after standard treatments.
Dallas, TexasAges 18 years+
Solid Tumors (Phase 1) trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting solid tumors (phase 1) studies listed above.
- The University of Texas MD Anderson Cancer Center · 10 studies
- NEXT Oncology · 9 studies
- Baylor College of Medicine · 2 studies
- Mary Crowley Cancer Research · 2 studies
- Research Site · 2 studies
- START San Antonio · 2 studies
- Texas Oncology · 2 studies
- Avenzo Therapeutics
What taking part in a solid tumors (phase 1) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there solid tumors (phase 1) clinical trials in Texas?
- Yes. We're currently tracking 157 recruiting solid tumors (phase 1) studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumors (phase 1) study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumors (phase 1) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumors (phase 1) studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.